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Re-engineering the laboratory
Frank Zenie
Zymark Corporatiom, Zymark Center, Hopkinton, MA 01748
This paper explains why, in today’s rapidly changing environment,
it is essential for organizations to re-engineer. The main drivers
behind business re-engineering are informed customers and
information technology. The author explains the changes needed in
management behaviour and performance and then describes, step
by step, how to re-engineer laboratories. Finally, the importance
ofpartnerships is stressed and explained by examples.
’If it ain’t broke, don’t fix it!’ We hear this all the time.
While it is intended to be prudent advice, it is based on
a flawed premise. It assumes that competitors, customers
and the economy will remain constant. Yet, given our
rapidly changing world, this cautious approach is really
a high risk philosophy. We either embrace change or
become followers of the new leaders.
Our organizations are changing more rapidly than ever
before--and the consequences range from success and
prosperity--to fragile survival--to economic failure.
Re-engineering is a process through which we can initiate
and direct change rather than react to changes created
by others.
Re-engineering business is not new, yet it is timely to meet
today’s challenges: ’In today’s environment, nothing is
constant or predictable--not market growth, customer
demand, product life cycles, the rate of technological
change, or the nature of competition... It is not products
but the processes that create products that bring companies
long term success. Good products don’t make winners;
winners make good products [1-]’.
Two primary forces driving these changes include:
(1) Informed customers--Informed customers demand more
value and, thereby, stimulate competition. Today’s
individual consumers and business purchasers are well
educated and demand higher quality, service and
value. Providers of products and services, therefore,
must re-earn customers’ business by providing in-
novative products and greater value.
Information technology (IT)--IT is a driving force and
an enabling technology facilitating innovation and
change. IT enables organizations to shift from
inefficient hierarchies to efficient teams working on
high leverage opportunities. Ever increasing globali-
zation, for example, is a strategic opportunity made
possible only through advances in IT.
Science cannot separate itselffrom business and economics.
Science creates the technology which drives our most
robust businesses. As competitive, consumer and regulatory
pressures force business to improve quality and produc-
tivity, science must lead, or at least enable, the bold steps
ahead.
Not too many years ago when a company hired a new
scientist, that scientist could purchase his or her favourite
instrumentation, computers and software. This is no
longer true. With today’s need for information sharing,
technology transfer and regulatory compliance, companies
must harmonize and standardize their use oftechnology.
Profit leverage---beyond cost reduction
Near term business challenges trigger restructuring
programmes to reduce costs and maintain profitability.
Longer term, focus will shift to re-engineering business
processes to make organizations more productive by
creating greater customer value.
To begin, we need new definitions and measurements of
costs. In the past, we turned to the accountants to measure
the ’cost’ of our decisions. ROI (Return on Investment)
became the commonly accepted measure to evaluate
investment opportunities. Yet, ROI only recognizes
accounting costs.
Accounting costs are tangible and relatively easy to measure
and control--much of today’s downsizing, for example,
is focused on reducing accounting costs. Opportunity costs,
on the other hand, include intangible and indirect costs
including the lost income from missed business oppor-
tunities. Only time will tell if the opportunity costs of
today’s decisions exceed the short term accounting
savings. Both accounting costs and opportunity costs are
real! Just because intangible costs may never, or not until
some time in the future, be recognized through accounting,
does not diminish their strategic impact. More often than
not, the highest business leverage relates to opportunity
costs of missed business opportunities.
Effective use of time and resources are critical, therefore,
faster time to market becomes a strategic initiative to
maximize the return on successful projects. While more
difficult to measure, ’failing fast’ saves opportunity costs
and permits reallocating valuable resources from a failed
project onto a new, more promising one. Sooner is
generally better than later.
These driving forces are irreversible and relentless, that
is, they will never return to the past. Regulation, on the
other hand, is often a political and even emotional driving
force. We have seen many examples where the desired
benefits ofregulation are better attained through education
and economic incentives.
Accelerating change in chemistry
Modern chemistry began with exciting discoveries during
and following the Second World War. Over the past 10
to 20 years, we have been digesting and applying these
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new technologies. Nowhere is this more evident than in
drug discovery--driven by the huge economic reward for
powerful new therapies.
During the 1980s, scientists recognized the analytical
power of computers and many extended this power to
computerized molecular development--rational drug
design. Molecular and therapeutic knowledge proved
insufficient to meet this challenge and few, if any, drugs
were discovered through purely rational processes.
Entering the 1990s, pharmaceutical and biotechnology
scientists and executives recognized that they had to
return to the drug discovery techniques that created most
modern drugs and apply new technology to make these
techniques far more productive.
Using 1990 for reference, typical drug screening projects
completed 10000 to 20000 assays per year against one
target. Large pharmaceutical companies with large
compound libraries (100 000 to 200 000 compounds) were
well stocked and their organic synthesis staff were adding
50 to 100 compounds per year per scientist.
Today, High Throughput Screening (HTS) can perform
500000 to 000000 assays per year, often with multiple
targets. Automated organic synthesis (combinatorial and
parallel synthesis techniques) can produce thousands of
compounds per week. These two revolutions, combined
with powerful data management innovations, make
today’s drug discovery efforts three to five orders of
magnitude more productive than those at the start of this
decade.
Technologymenabling re-engineering
The goal should now be to increase productivity--that
is create more economic value for each unit of cost. This
is different from cost reduction. Wherever possible, people
and automation should be teamed for productivity.
Re-engineering involves a systematic assessment of
cross-functional, work flow processes which stimulate
creative approaches to streamline the processes, introduce
innovation and to eliminate unnecessary steps and
hand-offs. New technologies enable more creative re-
engineering solutions.
The dramatic productivity gains in drug discovery, for
example, were enabled by technology advances (see table
1). New technology is increasing drug discovery produc-
tivity by several orders of magnitude compared to a few
years ago. With more leads and more powerful lead
optimization, more and better drug candidates will
require development support--further challenging devel-
opment resources. Again, technology is enabling develop-
ment to meet this challenge, for example, bioanalytical
support ofclinical trials (see table 2). Independently, each
of the technologies in table 2 contributes incremental
productivity. When combined in a new process, however,
far greater productivity improvements become possible.
Figure illustrates the relative costs for gaining each
increment of productivity benefit. When driven by
technology or people reduction, we often push into the
region ofdiminishing leverage. In laboratory automation,
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Table 1. Enabling technologiesfor drug discovery.
Technology Benefit
Innovative screening assays
and automated high
throughput screening (HTS)
Automated organic synthesis
and combinatorial chemistry
Automated compound
preparation and distribution
Computers and data
management
Automated structural
characterization
One to two orders of
magnitude increase in
screening capability.
Two to three orders of
magnitude increase in
compounds for HTS. More
diverse compound arrays.
Capacity to provide large
numbers of compounds for
HTS. Create and access
compound data base.
Tracking and analysing
discovery data. Global
integration of drug discovery
programmes.
Timely availability of
improved compound
knowledge for screening and
lead optimization.
Table 2. Enabling technologies for bioanalytical analysis.
Technology Benefit
Overnight package delivery
Communications and
information systems
LC/MS/MS
High throughput extraction
and concentration
Timely delivery of supplies to
the clinic and timely delivery of
patient samples to the
laboratory.
Real time information sharing.
Very fast (2-5 minutes per
sample), high resolution
analysis of biological samples.
Rapid methods development.
Dramatic increase in sample
preparation throughput,
improved analytical data and
less solvent consumption for
bioanalytical methods. Rapid
methods development and
optimization.
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this translates into increasing complexity, higher cost and
decreasing reliability. The most successful laboratory
automation projects focus on the ’high value region’.
When a little automation is good, it does not mean a lot
of automation is better.
Management role
Today, improving productivity is management’s primary
mission. In the early phase of the industrial revolution,
managers adopted the military command and control
model--managers controlled workers who performed
physical tasks. Over time, physical work was transferred
to machines and workers gained more education to
become ’knowledge workers’. Following this, expert
knowledge workers became managers to manage special-
ized functions. Hierarchical organizations evolved to
control work and facilitate the flow of information. Until
recently, managers focused on specialized tasks rather
than cross-functional processes which produced value. It
is not surprising that serving customers got lost.
The industrial revolution is now the information revolution.
Leadership is no longer defined by hierarchical position.
Productivity and value must be viewed within a work
flow process, not limited by functional boundaries.
Leaders bring knowledge, commitment, and shared values
and purpose. ’Managers stop acting like supervisors and
behave more like coaches. Workers focus more on the
customers’ needs and less on their bosses’ [2].
Management survey
In order to gain further insights into management’s
perspective on laboratory automation, I surveyed a small
group of senior managers for their observations. The
managers were directors, senior directors and divisional
vice presidents. The survey group was limited to indi-
viduals with direct experience with laboratory automation
in their areas and a management vision relating to
strategic impact. Twenty managers responded, from four
functional areas: drug discovery; analytical R&D; bio-
analytical R&D; and quality assurance/quality control.
The survey explored automation objectives and desired
improvements to make automation more valuable. Survey
participants rated each topic at one of three levels: very
important, important, or relatively unimportant. Since
the survey group was small, the summary results in table
3 are shown as relative responses.
Table 3 shows that laboratory automation’s primary
objective is to increase laboratory capacity for higher work
loads and increase productivity of limited staff. Faster
sample turnaround also was a shared priority. As
expected, R&D managers see laboratory automation
reducing new product time to market. Quality control
managers, on the other hand, focus on reducing manu-
facturing, cycle time and maintaining regulatory com-
pliance. Surprisingly, methods and technology transfer
was not seen as a strong objective for laboratory
automation (see table 4). Managers from all areas stressed
flexibility to meet rapidly changing needs. Most likely,
R&D managers emphasize flexibility in order to adapt to
new projects and new technologies, while QC managers
need flexibility to automate a growing number ofmethods
needed for broader product lines and smaller manu-
facturing batches required by rapidly changing market
demand.
Laboratory re-engineeringma systematic process
Getting ready
Prior to solving any problem, we must gain agreement
that there is a problem and that it is worth solving. Only
then, can we begin the solution process. Re-engineering
is a solutions process that demands intellectual contribu-
tions and commitment from the people involved. Without
this, don’t start.
Effective laboratory re-engineering requires systematic
analysis and creative solution development. Defining
process boundaries is critical; if too narrow, the solution
Table 3. Management survey.
Automation objectives All R&D QA/QC
Increased capacity for higher work loads
Increased productivity--lower cost or staffing limitations
Financial returns--ROI
Development--reduce time to market
Faster sample turnaround
Improved precision documentation and audit trails (validation)
Improved data management
Regulatory compliance
Facilitate methods transfer--analytical to QC, multisite, outsourcing
Global unification of lab methods
Reduce the use of contract labs
Reduce manufacturing cycle time
Staff motivation and job enrichment
Staff safety
Better space utilization
High + High + High +
High + High + High /
Moderate Moderate Moderate
Moderate High Low
High High High
Moderate Moderate High
Moderate Moderate Moderate
Moderate Low Moderate
Moderate Low Moderate
Low Low Low
Low Low Low
Moderate Low High
Moderate Moderate Moderate
Moderate Moderate Moderate
Low Low Low
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Table 4. Improvements which would make laboratory automation
more valuable.
All R&D QA/QC
Improved reliability High High High
Ease of use and faster High High High
implementation
Flexibility--reconfigure High / High / High +
for new applications
More powerful connectivity Moderate Moderate Moderate
Improved methods Moderate Moderate Moderate
development capabili,ty
Lower cost Moderate Moderate Moderate
may have limited impact and, if too broad, the solution
may be too difficult to implement. Fortunately, people
working in the area of interest typically understand the
issues and problems. Re-engineering leaders, in most cases,
serve as facilitators extracting and analysing readily
available information. The re-engineering process follows
four phases: situation analysis; identify solutions and
opportunities; select high leverage solutions; and imple-
mentation-plan and execution.
Process trends assessment
The next step in situation analysis requires analysis of
process trends and complexity. Highly complex processes
tend to become inefficient and unpredictable. Table 5 is
an approach to identify process trends and complexity in
a pharmaceutical manufacturing and QC situation. Using
the definitions in table 5, an individual organization can
graphically highlight its process trends and complexity
under current conditions and projected at some appro-
priate time in the future. Table 6 illustrates the following
process trends:
(1) The number of different products is growing due to
new products and the transfer of some existing
products to this manufacturing site.
(2) Even though the number of products is growing, the
manufacturing plants are specializing in specific
dosage forms.
(3) The company wants to be more responsive to market
demand, yet it wants lower inventories and faster
cycle time. The company, therefore, will produce
smaller batches in response to current market demand.
(4) The fundamental manufacturing process will not
change greatly.
(5) Analytical methods are becoming more complex to
meet regulatory demands.
(6) New product introductions will increase over historical
levels.
Situation analysis
Process mapping graphically highlights work flow,
hands-off and redundant activities. The generic process
map, shown in figure 2, illustrates two critical pharma-
ceutical industry processes and their organizational
interactions. First, is the manufacturing/quality-control
process focused on the flow of raw materials through
finished products released for distribution. The second,
illustrates the analytical methods development process
from early development to NDA filing and to QC for
global, multiplant use. Beginning with this generic process
map. It is easy to modify it to represent each organization
specific work flow.
Product leverage assessment
just as process trends help identify re-engineering
opportunities, product trends offer additional insights (see
figure 3). The product leverage assessment in figure 3
indicates the re-engineering insights in Table 7.
Identify solutions/opportunities
This phase of re-engineering is illustrated in table 8.
Select high leverage solutions
The symptom-cause-solutions process identifies many
potential solutions. The highest leverage solutions should
Manufacturing &
Distribution Vendors
Quality Assurance-
Quality Control
Rav Processing 1 htve &
Materials See Note Packaging ----lstribution
QC Laboratory Operations Release & Stability
Tech. Service Methods Development& Validation
Process Validation
Analytical Laboratories
AnalyticalR&D IFormulations Development, Stability& NDA Submissions
IPre-clinical, Phase I, Phase II, Phase III and Phase IV
Methods Development& Validation
Figure 2. Process mapping.
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Table 5.
Process complexity Low Moderate Substantial High
Number of different products produced
Dosage form varieties
Planning complexity--demand variations--
peaks and valleys
Complexity of individual process steps--yield
Analytical complexity
New product introductions
One or two related
Single
Uniform and
predictable
demand
Simple and stable
Simple and fast,
can be performed
by operator
None
Several related
Several related
Variable, but
with planning
lead time
Somewhat
complex, but
robust
Reliable, but
requires trained
technician
Occasional and
related to current
products
Several related
Some unrelated
Several, some
unrelated
Variable, with
little lead time
Complex--not
robust
Technique
dependent,
requires skilled
analyst
Several per year,
but
related to current
products
Many and
unrelated
Multiple and
diverse
Unpredictable
reactive planning
Complex--not yet
robust
Utilize new
techniques,
requires methods
development
support
Several per year
requiring new
processes and
analyses.
Table 6.
Process complexity Low Moderate Substantial High
Number of different products produced
Dosage form varieties
Planning complexity--demand variations--peaks
and valleys
Complexity of individual process steps--yield
Analytical complexity
New product introductions
0 >0
0 ,O
O Today
Projected 3 years.
be selected for implementation from these. Figure 4 is
a useful model for selecting high leverage solutions. Not
only do the highest leverage solutions deliver high value,
they also establish credibility for the process and the
participants.
Manufa Volume (Batches/Tune)
High
Medim
Low
Low Medium
Process and Analytical Complexity
Add arrows forTrends: None Low
High
Moderate High
Figure 3. Manufacturing volume (batches/time).
Implementation
Shortcuts often lead to wasted money, time and resources.
Figure 5 illustrates Zymark’s solutions implementation
process for laboratory automation projects. It emphasizes
planning, management involvement, training and long-
term support. Earlier technology’s role for enabling
re-engineering was highlighted. For enduring success,
technology must be transferred to the operational
staff.
Partnering for productivity
The business world is changing and the traditional
buyer/seller relationship no longer meets many of today’s
challenges. Organizations are focusing their limited
resources on core competencies, and yet, non-core areas
are more complex than ever before. Innovative organiza-
tions will partner with specialized organizations to gain
access to the critical mass of knowledge and skilled
resources needed to address these issues.
Two examples illustrate the partnering trend. Biotech
companies are more and more becoming the research
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Table 7. Re-engineering insights.
Product Re-engineering leverage issues
Product A
Product B
Product C
Product D
Product E
Product F
Product G
High volume, low complexity. Probably very profitable. Re-engineering might make it even more productive.
Relatively high volume and moderate, but increasing complexity. Good candidate for re-engineering.
High volume, high complexity. Good candidate for re-engineering.
Low, but increasing, volume and low complexity. Re-engineering might have an effect.
Low volume, high complexity. Consider dropping product unless high profit or strategically important. Less frequent,
larger batches might help productivity.
Moderate volume and complexity. Might benefit from re-engineering processes shared with other products.
Similar to F, but with decreasing volume. Probably not re-engineering candidate.
Table 8.
Symptom Possible causes Potential solutions
Schedule related
Delays
Late shipments
Cost related
Low yield
Scrap and reruns
Inventory cost--long
cycle time
Quality related
Reruns
Scrap
Compliance--reruns
and investigations
Late raw materials
Inadequate capacity--manufacturing or laboratory
Process unreliability--low or unpredictable yield
Poor work flow--too many hands-offs
Inadequate or uptrained staff
Insufficient or non-working equipment
Priority interruptions
Laboratory backlog--slow turnaround
Unreliable methods--reruns
Inefficient process
Inadequate capacity--manufacturing or laboratory
Process unreliability--low or unpredictable yield
Raw material quality
Human errors
Small batch size--wide product mix
Inadequate process control information
Process control
Raw materials or process materials
Unreliable processes or methods
Inadequate documentation
Improve vendor delivery performance
Improve process reliability
Reduce cycle time
Staffing--add, train, overtime, temps
Add equipment, preventive maintenance
Improved planning--decrease batch size
Improve work flow and/or laboratory methods
Introduce efficient, automated methods--multishift
operation and at-line testing
Reduce unnecessary handling, transfers and delays
Improve process efficiency, increase batch size
Vendor certification
Introduce in-process testing to reduce scrap
Introduce efficient, automated methods--multishift
operation--more timely information at lower
cost
Introduce at-line testing--faster release
In-process testing
Introduce efficient, automated methods--more
robust analysis and documentation
partners for large, multi-national pharmaceutical com-
panies. The emerging biotech industry attracts entre-
preneurial scientists and executives, stimulates innovation
and retains the flexibility ofsmall organizations. The large
companies have the know-how and investment base for
High
Impact
Low
Highest Leverage
Fast Results
Excellent Candidate
Low Leverage
Poor Candidate
Low
High Leverage
Good Candidate
High
Cost- $, Resources and Risk
Figure 4. Modelfor selecting high leverage solutions.
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Solutions Implementation Process
Test& Improve Today’s
and
Hands-on ammg Solutions Strategy Senior Management
Project Scope Workshop Presentation
Workshop
Technology Transfer---- Empowerment
Figure 5. Solutions implementation process.
clinical trials, product development, manufacturing and
distribution. CROs (contract research organizations) are
also becoming more complete partners for the design and
implementation of clinical trials.
Organizations cannot simply decide to partner. They
must develop relationships, share information and trust
each other. The path to partnering is: transaction
solution -
partnering.Frank Zenie Re-engineering the laboratory
Solutions--products and value-added services
A product, no matter how technology rich, is only part
of a solution. Today’s solutions are product/service
packages. Four examples highlight Zymark’s solutions
strategy in laboratory automation:
(1) ISLAR--A strong educational and networking forum
for sharing experiences and knowledge of laboratory
automation. In addition, ISLAR is becoming a
vehicle to stimulate technology transfer within
customer organizations.
(2) AiS automation and integration services) program--A
training programme which enables customer automa-
tion specialists to access and apply Zymark technology
at the component and module level.
(3) Validation consulting--Many pharmaceutical develop-
ment and manufacturing processes must be validated
under current good manufacturing practices (cGMP)
required by the FDA in the USA. As laboratory
automation became widely used, pharmaceutical
companies were faced with two problems. First, to
determine what is required to validate laboratory
automation equipment and second, providing the
resources to perform the validation. Clearly, it was
more efficient for the manufacturers of laboratory
automation to apply validation principles to their
technology, develop compliant validation protocols
and offer professional services to perform the valida-
tion. This solution combines both knowledge and
resources.
(4) Automated Q.C release testing--A tailored package of
automated workstations, methods optimization, train-
ing, validation and data management for the QC
release of pharmaceuticals. This technology enables
the additional step of transferring release testing from
the central control laboratory to at-line testing.
Partnering--interdependent relations
At Zymark, we had the opportunity to participate in
research conducted by Huthwaite, Inc., a leading
research-based sales and management consulting firm.
Their research into partnering was published in a book
Getting Partnering RightmHow Market Leaders are Creating
Long-Term Competitive Advantage published by McGraw-
Hill. Huthwaite defines partnering as the ways that
corporations are working with each other to create value.
Their research identifies three ingredients for successful
partnering: vision; impact; and intimacy (see figure 6).
The Ingredients for Successful Partnering
Vision
of the possibilities
Impact Intimacy
adding real closeness
productivity sharingand
& value mutual trust
Figure 6. Successful partnerships.
Partnering clearly steps beyond the traditional transaction-
based relationships. Partnering is not discounting, but
includes a sharing of the savings achieved by the closer
relationship. Partnering is not appropriate for all organi-
zations or for all aspects of their business. A partnering
relationship opens new alternatives to collaborate for
productivity, for example:
(1) Re-engineering consulting for cross functional pro-
cesses--Collaborating with analytical R&D and
quality control to introduce automation earlier in the
development process. Providing improved methods
development tools and support to lower the entry
threshold for laboratory automation. Making labor-
atory automation part of the NDA process for more
effective NDA filings and to facilitate.later stage
development and QC needs for larger sample loads.
Collaborating with manufacturing and QC to stream-
line the in-process and release.testing to shorten the
manufacturing cycle and lower testing cost under full
cGMP compliance.
(2) Creating an alternative to outsourcing and contract
laboratories; such as ’in-sourcing’, a virtual contract
laboratory providing the benefits of outsourcing with
increased management control and lower, but still
variable, cost.
(3) Joint development ofnew automation technology for
organic synthesis--flexible and concurrent with
chemistry developments.
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